Biosynex S.A.
ALBIO.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.02 | -0.01 | 0.06 |
| FCF Yield | 0.00% | -8.19% | -50.99% | -9.02% |
| EV / EBITDA | -57.28 | -8.28 | -66.99 | -12.15 |
| Quality | ||||
| ROIC | -0.62% | 0.00% | 0.00% | -16.27% |
| Gross Margin | -0.59% | -19.79% | -19.74% | 50.99% |
| Cash Conversion Ratio | -0.06 | 0.54 | -0.03 | 0.52 |
| Growth | ||||
| Revenue 3-Year CAGR | -20.09% | 1.06% | 29.02% | 64.10% |
| Free Cash Flow Growth | 0.00% | 88.78% | -89.15% | 83.10% |
| Safety | ||||
| Net Debt / EBITDA | -57.28 | -6.28 | -45.95 | -4.44 |
| Interest Coverage | -0.20 | -2.22 | -6.53 | -29.43 |
| Efficiency | ||||
| Inventory Turnover | 1.96 | 1.48 | 1.71 | 0.65 |
| Cash Conversion Cycle | 53.80 | 49.65 | 47.96 | 103.48 |